Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Melanoma 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Glioma 1Ependymoma 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Sorafenib 29Nivolumab 15pembrolizumab 12Radiosurgery 9Bevacizumab 9atezolizumab 7regorafenib 5Radiotherapy 5Fluorouracil 5Doxorubicin 5lenvatinib 4Sunitinib 4Oxaliplatin 4Ipilimumab 4Gemcitabine 4Ethiodized Oil 4Erlotinib Hydrochloride 4Capecitabine 4TLC 388 3Radiofrequency Ablation 3Leucovorin 3Everolimus 3Cisplatin 3Blood Specimen Collection 3toripalimab 2phosphomannopentaose sulfate 2durvalumab 2cediranib 2avelumab 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Hepatocellular × AZD 6244 × Clear all
NCT01029418 2015-04-16

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

National Cancer Centre, Singapore

Phase 1/2 Terminated
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡